cns 5161 has been researched along with Neuralgia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higaki, K; Kimura, T; Konishi, R; Naruse, M; Ogawara, K | 1 |
| Forst, T; Marcus, P; Pfützner, A; Schütte, K; Smith, T | 1 |
2 other study(ies) available for cns 5161 and Neuralgia
| Article | Year |
|---|---|
Development of transdermal therapeutic formulation of CNS5161, a novel NMDA receptor antagonist, by utilizing pressure-sensitive adhesives II: improved transdermal absorption and evaluation of efficacy and safety.
Topics: Adhesives; Adjuvants, Pharmaceutic; Administration, Cutaneous; Analgesics; Animals; Guanidines; In Vitro Techniques; Irritants; Male; Neuralgia; Permeability; Pressure; Rabbits; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Silicones; Skin; Skin Absorption; Skin Irritancy Tests; Sulfhydryl Compounds; Treatment Outcome | 2014 |
Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain.
Topics: Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Guanidines; Humans; Male; Middle Aged; Neuralgia; Pain Measurement; Receptors, N-Methyl-D-Aspartate; Sulfhydryl Compounds | 2007 |